Modalis Therapeutics Corporation (TYO:4883)

Market Cap	4.99B -20.2%
Revenue (ttm)	n/a
Net Income	-2.15B
EPS	-27.85
Shares Out	87.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	696,100
Average Volume	705,565
Open	58.00
Previous Close	58.00
Day's Range	57.00 - 60.00
52-Week Range	52.00 - 119.00
Beta	0.13
RSI	50.35
Earnings Date	May 8, 2026

About Modalis Therapeutics

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology developed by Modalis that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorpor...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 17
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4883